Functional ultrasound imaging to study brain dynamics: Application of pharmaco-fUS to atomoxetine

Vidal, Benjamin; Droguerre, Marine; Venet, Ludovic; Zimmer, Luc; Valdebenito, Marco; Mouthon, Franck; Charvériat, Mathieu

doi:10.1016/j.neuropharm.2020.108273

Cited by 16 publications

(9 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, combining neurofunctional imaging with ultrasound can be an optimal option [83]. FUS, a new mobile neuroimaging modality with unprecedented spatiotemporal resolution [84][85][86], permits brain activity imaging by monitoring transient changes in cerebral blood volume dynamics that mirror the changes in metabolic activity of activated neurons through neurovascular coupling (Table 5). Notably, Mace et al demonstrated that FUS allowed for precise localization of the functional area of the cerebral cortex, which can help facilitate maximum tumor resection and preserve the functional area, thereby reducing postoperative compli-cations and improving patients' quality of life [83].…”

Section: Ultrasound Elastography Ultrasonography Had Been Firstmentioning

confidence: 99%

Application of Multiparametric Intraoperative Ultrasound in Glioma Surgery

Shi

Zhang

Yao

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Gliomas are the most invasive and fatal primary malignancy of the central nervous system that have poor prognosis, with maximal safe resection representing the gold standard for surgical treatment. To achieve gross total resection (GTR), neurosurgery relies heavily on generating continuous, real-time, intraoperative glioma descriptions based on image guidance. Given the limitations of currently available equipment, developing a real-time image-guided resection technique that provides reliable functional and anatomical information during intraoperative settings is imperative. Nowadays, the application of intraoperative ultrasound (IOUS) has been shown to improve resection rates and maximize brain function preservation. IOUS, which presents an attractive option due to its low cost, minimal operational flow interruptions, and lack of radiation exposure, is able to provide real-time localization and accurate tumor size and shape descriptions while helping distinguish residual tumors and addressing brain shift. Moreover, the application of new advancements in ultrasound technology, such as contrast-enhanced ultrasound, three-dimensional ultrasound, navigable ultrasound, ultrasound elastography, and functional ultrasound, could help to achieve GTR during glioma surgery. The current review describes current advancements in ultrasound technology and evaluates the role and limitation of IOUS in glioma surgery.

show abstract

Section: Ultrasound Elastography Ultrasonography Had Been Firstmentioning

confidence: 99%

Application of Multiparametric Intraoperative Ultrasound in Glioma Surgery

Shi

Zhang

Yao

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…A newer tool, pharmaco‐fUS enables brain activity imaging through the local monitoring of cerebral blood volume dynamics at an unprecedented spatiotemporal resolution without the bias of anesthesia 462,463 . Recent studies demonstrated fUS imaging's potential to characterize dynamic profiles of CNS drugs, including a drug combination of donepezil plus mefloquine for AD 464 and atomoxetine for attention‐deficit/hyperactivity disorder 465 . Moreover, Rabut et al 466 .…”

Section: Discussionmentioning

confidence: 99%

Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions

Vatansever

Schlessinger

Wacker

et al. 2020

Medicinal Research Reviews

180

View full text Add to dashboard Cite

Neurological disorders significantly outnumber diseases in other therapeutic areas. However, developing drugs for central nervous system (CNS) disorders remains the most challenging area in drug discovery, accompanied with the long timelines and high attrition rates. With the rapid growth of biomedical data enabled by advanced experimental technologies, artificial intelligence (AI) and machine learning (ML) have emerged as an indispensable tool to draw meaningful insights and improve decision making in drug discovery. Thanks to the advancements in AI and ML algorithms, now the AI/ML‐driven solutions have an unprecedented potential to accelerate the process of CNS drug discovery with better success rate. In this review, we comprehensively summarize AI/ML‐powered pharmaceutical discovery efforts and their implementations in the CNS area. After introducing the AI/ML models as well as the conceptualization and data preparation, we outline the applications of AI/ML technologies to several key procedures in drug discovery, including target identification, compound screening, hit/lead generation and optimization, drug response and synergy prediction, de novo drug design, and drug repurposing. We review the current state‐of‐the‐art of AI/ML‐guided CNS drug discovery, focusing on blood–brain barrier permeability prediction and implementation into therapeutic discovery for neurological diseases. Finally, we discuss the major challenges and limitations of current approaches and possible future directions that may provide resolutions to these difficulties.

show abstract

“…Pharmacological MRI is therefore increasingly used in CNS drug development to predict mechanisms of drug efficacy and safety in animals and humans, including healthy volunteers and patients (Mandeville et al, 2014). Neuropharmacology is also a highly promising application domain for fUS (pharmaco-fUS) to address the CNS effects of drugs, at least in animals (Rabut et al, 2020;Vidal et al, 2020).…”

Section: Hybrid Protocols For Synchronized Neuroimagingmentioning

confidence: 99%